Dr Reddys Laboratories Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 31 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.0L Cr

Emerging Markets expected to grow with new product launches and higher volumes, led by Rest of World and favorable currency movements. The company targets an adjusted EBITDA margin close to 25%, aided by launches, business development, and cost optimization (Page 5).

From Dr Reddys Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹1,175

Market Cap

₹1.0L Cr

P/E Ratio

31.1

How does Dr Reddys Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Dr Reddys Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Dr Reddys Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹7.5K Cr, net profit ₹221 Cr.

Full financials →

📊 Revenue & Sales Performance

→Emerging Markets expected to grow with new product launches and higher volumes, led by Rest of World and favorable currency movements.
→India business projected to deliver robust double-digit growth, driven by innovation franchise, new brand launches, price increases, and volume growth.
→US business to grow in double digits ex-lenalidomide, supported by biosimilars, consumer health, and 505(b)(2) products.
→Semaglutide sales expected to reach around 12 million units in FY27, with potential growth also in emerging markets beyond India.
→Biosimilars like abatacept expected to contribute to growth, with break-even targeted post-launch (around FY28).
→Continued focus on launching new products globally (27 new product launches planned in the US for FY27).
→Nicotine Replacement Therapy (NRT) business growing mid to high single digits.
→Overall contribution from innovation franchises like semaglutide to push gross margins and revenue growth towards mid to high teens or higher.

📈 Profitability & Margins

→The company targets an adjusted EBITDA margin close to 25%, aided by launches, business development, and cost optimization (Page 5).
→Base business margin (excluding semaglutide) planned around 20%, with semaglutide expected to push margins near 25%, depending on sales volume and mix (Page 15).
→EPS diluted for FY26 was ₹51.42; no explicit forward EPS guidance provided but margin improvements and growth drivers indicate positive trajectory (Page 5).
→Double-digit growth expected in North America ex-lenalidomide and ex-semaglutide for FY27 (Page 11, 15).
→Base business growth momentum expected to sustain with double-digit expansion (Page 3, 7).
→Gross margins expected above 50% in FY27, supported by semaglutide and new product launches (Page 10).
→Investments in biosimilars and peptide innovation to support future growth; abatacept launch expected in FY28 (Page 12).
→R&D spend expected at 7-8% of revenues in fiscal ahead to fuel pipeline progression (Page 4).

🏗️ Capital Expenditure Plans

→The annual capex plan for the next year is around ₹2,000 crores.
→Investment will be largely focused on biosimilars, certain product-specific investments, and general capex.
→Continued strategic investments include partnerships for biologics development to share R&D costs.
→There is potential capacity expansion, e.g., qualifying capacity at FTO11 by FY28 to increase production (possibly up to 40 million units), but current demand does not yet require this.
→Ongoing targeted investments in branded franchises, such as Nicotine Replacement Therapy (NRT) and branded generics, to support long-term growth.
→R&D investments expected to decrease following abatacept Phase III completion, with future biologics mostly developed with partners.
→Use of Artificial Intelligence (AI) aims to increase R&D productivity and reduce overall costs.

💰 Fundraising & Capital Structure

→There is no specific mention of any current or planned future fundraising through debt or equity in the Q3FY26 earnings call transcript.
→The company highlights having a net cash surplus of ₹3,271 crores (US$349 million) as of March 31, 2026, indicating a strong liquidity position.
→Capex plans for the next year are around ₹2,000 crores, funded through internal resources.
→The management focuses on operational efficiencies, strategic investments in pipeline programs, and inorganic growth via business development rather than explicit fundraising.
→No indication of issuing new equity or taking on additional debt was disclosed during the call.

📋 Order Book & Pipeline

The transcript does not explicitly mention specific figures or details regarding the current or expected order book or pending orders. However, from the context: - The company is actively launching multiple products across various markets including semaglutide, biosimilars, and others. - For semaglutide, they are expecting sales of around 12 million units in FY27 across over 50 markets, expanding to more than 80 markets within 12 months. - Biosimilar products like abatacept are anticipated to launch by CY2027 (FY28) which will drive substantial sales growth. - The company highlights strong momentum and a robust pipeline but specific quantitative details on order backlog or pending orders are not disclosed in the call. Thus, no direct data on orderbook or pending orders was provided in the earnings call transcript.

Key Metrics

What Dr Reddy's Labs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Dr Reddys Laboratories Ltd Q4 FY26 results?

What is Dr Reddys Laboratories Ltd share price analysis?

Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.1 with a market cap of ₹100,161 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Reddys Laboratories Ltd planning capital expenditure?

The annual capex plan for the next year is around ₹2,000 crores.

Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.